Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

De-escalation of immunomodulator and biological therapy in inflammatory bowel disease
Thomas Chapman, C Frias Gomes, Édouard Louis, et al.
˜The œLancet. Gastroenterology & hepatology (2019) Vol. 5, Iss. 1, pp. 63-79
Open Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

European Crohn’s and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation
Joana Torres, María Chaparro, Mette Julsgaard, et al.
Journal of Crohn s and Colitis (2022) Vol. 17, Iss. 1, pp. 1-27
Open Access | Times Cited: 166
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial
Édouard Louis, Matthieu Resche‐Rigon, David Laharie, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 3, pp. 215-227
Open Access | Times Cited: 57
Transient Mild Photothermia Improves Therapeutic Performance of Oral Nanomedicines with Enhanced Accumulation in the Colitis Mucosa
Ya Ma, Shuangquan Gou, Zhenhua Zhu, et al.
Advanced Materials (2023) Vol. 36, Iss. 14
Open Access | Times Cited: 25
Mulberry Biomass-Derived Nanomedicines Mitigate Colitis through Improved Inflamed Mucosa Accumulation and Intestinal Microenvironment Modulation
Wenjing Yang, Ya Ma, Haiting Xu, et al.
Research (2023) Vol. 6
Open Access | Times Cited: 24
Probiotics for the treatment of ulcerative colitis: a review of experimental research from 2018 to 2022
Cuilan Huang, Wujuan Hao, Xuyang Wang, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 21
ECCO Topical Review on Biological Treatment Cycles in Crohn’s Disease
Nurulamin M Noor, Paula Sousa, Dominik Bettenworth, et al.
Journal of Crohn s and Colitis (2023) Vol. 17, Iss. 7, pp. 1031-1045
Open Access | Times Cited: 17
Progressing advanced therapies for inflammatory bowel disease: Current status including dual biologic therapy and discontinuation of biologics
Kazuo Yashima, Hiroki Kurumi, Naoyuki Yamaguchi, et al.
Expert Review of Gastroenterology & Hepatology (2025)
Closed Access
Serum lipid profiles and risk of colorectal cancer: a prospective cohort study in the UK Biobank
Zhe Fang, Ming-Ming He, Mingyang Song
British Journal of Cancer (2020) Vol. 124, Iss. 3, pp. 663-670
Open Access | Times Cited: 48
MUC1-C drives stemness in progression of colitis to colorectal cancer
Wei Li, Ning Zhang, Caining Jin, et al.
JCI Insight (2020) Vol. 5, Iss. 12
Open Access | Times Cited: 47
Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease
J Schultheiss, Remi Mahmoud, J Louwers, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 54, Iss. 10, pp. 1298-1308
Open Access | Times Cited: 39
Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease
Remi Mahmoud, H. Schultheiss, J Louwers, et al.
Clinical Gastroenterology and Hepatology (2022) Vol. 20, Iss. 11, pp. 2577-2587.e6
Open Access | Times Cited: 23
Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease
Archana Shubhakar, Bas C. Jansen, Alex Adams, et al.
Journal of Crohn s and Colitis (2023) Vol. 17, Iss. 6, pp. 919-932
Closed Access | Times Cited: 14
Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)
Francisco Rodríguez‐Moranta, Federico Argüelles‐Arias, Joaquín Hinojosa del Val, et al.
Gastroenterología y Hepatología (2024) Vol. 47, Iss. 5, pp. 522-552
Open Access | Times Cited: 4
Exosomes derived from human umbilical cord mesenchymal stem cells regulate lymphangiogenesis via the miR-302d-3p/VEGFR3/AKT axis to ameliorate inflammatory bowel disease
Lu Zhang, Jintao Yuan, Dickson Kofi Wiredu Ocansey, et al.
International Immunopharmacology (2022) Vol. 110, pp. 109066-109066
Closed Access | Times Cited: 19
Serum Immune Profiling in Paediatric Crohn’s Disease Demonstrates Stronger Immune Modulation With First-Line Infliximab Than Conventional Therapy and Pre-Treatment Profiles Predict Clinical Response to Both Treatments
M Jongsma, L M M Costes, Irma Tindemans, et al.
Journal of Crohn s and Colitis (2023) Vol. 17, Iss. 8, pp. 1262-1277
Open Access | Times Cited: 11
The role of complex interactions between the intestinal flora and host in regulating intestinal homeostasis and inflammatory bowel disease
Siyu Li, Xu Kan, Yi Cheng, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 11
Inflammatory bowel disease evolution in the past two decades: a chronological multinational study
Pezhman Alavine­jad, Seyed Jalal Hashemi, Nitin Behl, et al.
EClinicalMedicine (2024) Vol. 70, pp. 102542-102542
Open Access | Times Cited: 3
Discontinuation of therapy in inflammatory bowel disease: Current views
Antonio Meštrović, Marko Kumrić, Joško Božić
World Journal of Clinical Cases (2024) Vol. 12, Iss. 10, pp. 1718-1727
Open Access | Times Cited: 3
Navigating Reproductive Care in Patients With Inflammatory Bowel Disease: A Comprehensive Review
Paula Sousa, Javier P. Gisbert, Mette Julsgaard, et al.
Journal of Crohn s and Colitis (2024) Vol. 18, Iss. Supplement_2, pp. ii16-ii30
Open Access | Times Cited: 3
Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology
Konstantinos Papamichael, Adam S. Cheifetz
Current Opinion in Rheumatology (2020) Vol. 32, Iss. 4, pp. 371-379
Open Access | Times Cited: 27
Discovery of biomarker candidates associated with the risk of short-term and mid/long-term relapse after infliximab withdrawal in Crohn’s patients: a proteomics-based study
Nicolas Pierre, Dominique Baiwir, Vân Anh Huynh‐Thu, et al.
Gut (2020) Vol. 70, Iss. 8, pp. 1450-1457
Open Access | Times Cited: 27
Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti‐TNF: a French nationwide study 2010–2018
Antoine Meyer, Jérôme Drouin, Alain Weill, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 54, Iss. 3, pp. 302-311
Closed Access | Times Cited: 25
Interleukin-17 and inflammatory bowel disease: a 2-sample Mendelian randomization study
Yangke Cai, Xuan Jia, Liyi Xu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
Hollow CeO2 with ROS-Scavenging Activity to Alleviate Colitis in Mice
Jing Yang, Jinzhe Zhou, Yingying Zhao, et al.
International Journal of Nanomedicine (2021) Vol. Volume 16, pp. 6889-6904
Open Access | Times Cited: 21
Unmet needs in inflammatory bowel disease
Joana Revés, Ryan C. Ungaro, Joana Torres
Current Research in Pharmacology and Drug Discovery (2021) Vol. 2, pp. 100070-100070
Open Access | Times Cited: 21
Page 1 - Next Page

Scroll to top